---
title: "Vivani Medical says first SLIM-1 dosing expected in August 2026 after CEO presentation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292906804.md"
description: "Vivani Medical announced that the first dosing of its drug candidate SLIM-1 is expected in August 2026. This information was disclosed during a presentation by CEO Dr. Adam Mendelsohn at the Emerging Growth Conference on July 15, 2026. The details were provided in a slide deck filed as Exhibit 99.1 under Regulation FD."
datetime: "2026-07-16T12:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292906804.md)
  - [en](https://longbridge.com/en/news/292906804.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292906804.md)
---

# Vivani Medical says first SLIM-1 dosing expected in August 2026 after CEO presentation

**Vivani Medical announced the company's first dosing of SLIM-1 is expected to occur in August 2026.**

**Key Highlights:**

-   CEO Dr. Adam Mendelsohn presented at the Emerging Growth Conference in New York on July 15, 2026.
-   Slide deck attached as Exhibit 99.1 discloses expected first dosing of SLIM-1 in August 2026.
-   Presentation is furnished under Regulation FD and speaks only as of the report date.
-   Company disclaims any obligation to update the slide presentation or incorporate it into future filings.

Original SEC Filing: Vivani Medical, Inc. \[ VANI \] - 8-K - Jul. 16, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [VANI.US](https://longbridge.com/en/quote/VANI.US.md)

## Related News & Research

- [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md)
- [What to Expect From Ulta Beauty’s Q2 2026 Earnings Report](https://longbridge.com/en/news/293941254.md)
- [Equatorial Energia updates financial calendar for 2026 disclosures](https://longbridge.com/en/news/294368263.md)
- [OSK: Q2 2026 sales rose 6.7% but margins declined; 2026 EPS guidance was revised lower](https://longbridge.com/en/news/294100394.md)
- [Ciena's Q3 2026 Earnings: What to Expect](https://longbridge.com/en/news/293952665.md)